Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab
Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.
In the largest data set of pregnancy outcomes for an anti-CD20 therapy in patients with multiple sclerosis (MS), results showed that in utero exposure to ocrelizumab (Ocrevus; Genentech) did not increase the risk of adverse pregnancy or infant outcomes. These data demonstrating ocrelizumab’s safety are significant considering pregnancies may occur during the 6-month interval between infusions.
These data were presented at the
Maternal ocrelizumab exposure was defined as at least 1 infusion, while potential in utero exposure was defined as less than 3 months prior to the last menstrual period or during pregnancy. Fetal death was termed spontaneous abortion (SA) If there was less than 22 complete gestational weeks (GW) or still birth (SB) if later. Among the 1144 prospective pregnancies for which outcomes were known, 83.6% were live births (LBs), 14 (1.2%) were ectopic pregnancies (EP), 58 (5.1%) were elective terminations (ET), 115 (10.1%) were SA, and 1 (0.1%) were SB.
Of the LBs recorded, 586 (61.3%) were full-term, 82 (8.6%) were preterm, and 288 (30.1%) had unknown GW. Of the 855 prospective pregnancies exposed in utero, 512 had known outcomes. Here, results showed that 84.2% were LB, 4 (0.8%) EP, 38 (7.4%) ET, 38 (7.4%) SA, and 1 (0.2%) SB. Sixteen (1.7%) major congenital abnormalities (MCAs) occurred in prospective LB, 9 of which had in utero exposure.
READ MORE:
Ocrelizumab has been FDA-approved since 2017 and remains the only marketed therapy to treat patients with primary progressive MS. Its original approval was for an intravenous infusion, supplied in 300 mg/mL single-dose vials. The initial dose is given as a 300 mg intravenous infusion over 2.5 hours, followed up with an additional 300 mg intravenous infusion 14 days later. Subsequent doses are given every 6 months as a 600 mg intravenous infusion over 3.5 hours.
More recently, the European Medicines Agency’s Committee for Medicinal Products for Human Use
The belief is that if approved, a SC administration of ocrelizumab will provide treatment flexibility and additional treatment options for patients and healthcare providers. In OCARINA, the SC and IV administration led to similar exposure overall during the first 12 weeks of treatment for the 116 patients who received each therapy in the study, with a geometric mean ratio comparing both arm’s area under the curve (AUC) of 1.29 (90% CI, 1.23-1.35; subcutaneous AUC weeks 1-12, 3500 µg/mL per day; IV AUC weeks 1-12, 2750 µg/mL per day).
Earlier this year, at the
REFERENCES
1. Bove R, Pietrasanta C, Oreja-Guevara C, et al. Pregnancy and infant outcomes in females receiving ocrelizumab for the treatment of multiple sclerosis: analysis of over 3000 pregnancies to date. Presented at: 2024 CMSC Annual Meeting; May 29-June 2; Nashville, TN. Abstract DMT05
2. Roche’s OCREVUS subcutaneous injection receives EU CHMP positive opinion for relapsing and primary progressive multiple sclerosis. News release. Roche. April 29, 2024. Accessed May 28, 2024. https://www.roche.com/investors/updates/inv-update-2024-04-29
3. Newsome SD. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase III OCARINA II Study. Presented at: MSMilan; October 11-13, 2023; Milan, Italy. POSTER P370.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025